Skip Navigation LinksHome > May/June 2009 - Volume 16 - Issue 3 > MF101, a selective estrogen receptor β modulator for the tre...
Menopause:
doi: 10.1097/gme.0b013e31818e64dd
Articles

MF101, a selective estrogen receptor β modulator for the treatment of menopausal hot flushes: a phase II clinical trial

Grady, Deborah MD, MPH1,2; Sawaya, George F. MD1; Johnson, Karen C. MD, MPH3; Koltun, William MD4; Hess, Rachel MD5; Vittinghoff, Eric PhD1; Kristof, Margaret MS, RN1; Tagliaferri, Mary MD, LAC6; Cohen, Isaac OMD, LAC6; Ensrud, Kristine E. MD, MPH7,8

Collapse Box

Abstract

Objective: To determine the optimal dose, safety, and efficacy of an estrogen receptor β selective Chinese herbal extract, menopausal formula 101 (MF101), for treating hot flushes.

Methods: A randomized, blinded trial in 217 postmenopausal women with hot flushes randomized to 5 or 10 g/day of MF101 or placebo for 12 weeks.

Results: The effects of 5 g/day of MF101 did not differ from those of placebo. After 12 weeks, the mean percent decrease in frequency of hot flushes in the 10 g/day group was 12.9% greater than that in the placebo group (P = 0.15), the median percent decrease was 11.7% greater than that in the placebo group (P = 0.05), and the proportion of women with at least a 50% reduction in hot flushes was 16.2% greater than that in the placebo group (P = 0.03).

Conclusions: Treatment with 10 g/day of MF101 reduces the frequency of hot flushes. Trials with higher doses are planned.

©2009The North American Menopause Society

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.